title: Glycogen synthase kinase 3 as an anticancer drug target: novel experimental findings and trends in the design of inhibitors.
abstract: Glycogen synthase kinase 3 (GSK-3) is a ubiquitous serine/threonine protein kinase participating in numerous pathways. Very important among them are cancer-related pathways, such as Wnt pathway and nuclear factor κB pathway. The recent findings concerning possible applicability of GSK-3 inhibitors as anticancer agents are summarized in this review, and controversies in the data are highlighted. The most actual concepts of GSK-3 inhibitor design are also thoroughly discussed.
authors.affiliation: Department of Chemistry, Lomonosov Moscow State University, Leninskie Gory 1/3, Moscow 119991 Russia.
authors.forename: Dmitry I
authors.initials: DI
authors.lastname: Osolodkin
authors.forename: Vladimir A
authors.initials: VA
authors.lastname: Palyulin
authors.forename: Nikolay S
authors.initials: NS
authors.lastname: Zefirov
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000494:pharmacology; D038362:Glycogen Synthase Kinase 3 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006801:Humans; D058990:Molecular Targeted Therapy; D016328:NF-kappa B / Q000378:metabolism; D009369:Neoplasms / Q000188:drug therapy / Q000201:enzymology; D060449:Wnt Signaling Pathway / Q000502:physiology
chemical_list: D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D016328:NF-kappa B; D038362:Glycogen Synthase Kinase 3